Compare SHIP & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHIP | HELP |
|---|---|---|
| Founded | 2008 | N/A |
| Country | Greece | Canada |
| Employees | N/A | 50 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.9M | 281.4M |
| IPO Year | 2008 | N/A |
| Metric | SHIP | HELP |
|---|---|---|
| Price | $11.97 | $4.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $17.00 | ★ $95.00 |
| AVG Volume (30 Days) | 273.3K | ★ 1.1M |
| Earning Date | 02-17-2026 | 07-01-2026 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.79 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.79 | $4.41 |
| 52 Week High | $14.93 | $8.55 |
| Indicator | SHIP | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 43.07 | 35.50 |
| Support Level | $7.85 | $4.47 |
| Resistance Level | $14.93 | $4.95 |
| Average True Range (ATR) | 0.63 | 0.34 |
| MACD | -0.18 | -0.03 |
| Stochastic Oscillator | 5.45 | 7.19 |
Seanergy Maritime Holdings Corp is an international shipping company that provides marine dry bulk transportation services through the ownership and operation of dry bulk vessels. It generates a majority of its revenue from the vessels. The company's fleet of vessels includes Blueship, Meiship, Kaizenship, Iconship, Titanship, Flagship, Paroship, Worldship, Hellasship, Partnership, Championship, Patriotship, Dukeship, Honorship, Fellowship, Knightship, Lordship, Premiership, Squireship, and Friendship.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.